Clinical Trial Update: Safety & Immunogenicity of GlaxoSmithKline Biologicals' Herpes Zoster Vaccine 1437173A [Phase 2]

View source ↗

Summary

A Phase 2 study of GlaxoSmithKline Biologicals' herpes zoster vaccine (1437173A) completed with results on safety and immunogenicity posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Herpes Zoster

Drugs mentioned

• Herpes Zoster Vaccine 1437173A (Herpes zoster vaccine)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Herpes Zoster | Phase 2 | Status: COMPLETED | Results posted: 2017-12-12